Century Therapeutics (IPSC) News Today $0.73 -0.02 (-2.52%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$0.76 +0.03 (+3.42%) As of 02/21/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $10.00 Consensus Price Target from AnalystsFebruary 21 at 1:47 AM | americanbankingnews.comFY2024 Earnings Estimate for IPSC Issued By Leerink PartnrsFebruary 18, 2025 | americanbankingnews.comLeerink Partnrs Has Strong Forecast for IPSC FY2024 EarningsCentury Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Equities research analysts at Leerink Partnrs boosted their FY2024 EPS estimates for Century Therapeutics in a research note issued on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnFebruary 17, 2025 | marketbeat.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Given Average Rating of "Buy" by AnalystsShares of Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) have earned an average rating of "Buy" from the six analysts that are presently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year target price among anFebruary 16, 2025 | marketbeat.comBrokers Offer Predictions for IPSC FY2029 EarningsFebruary 16, 2025 | americanbankingnews.comFY2029 Earnings Estimate for IPSC Issued By Leerink PartnrsCentury Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Leerink Partnrs issued their FY2029 earnings estimates for shares of Century Therapeutics in a note issued to investors on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch forecasts that the company will earn ($1.18) per shareFebruary 15, 2025 | marketbeat.comLeerink Partners Remains a Buy on Century Therapeutics (IPSC)February 14, 2025 | markets.businessinsider.comCentury Therapeutics SVP sells shares worth $273 to cover taxesFebruary 5, 2025 | msn.comCentury Therapeutics COO Farid Adrienne sells $822 in stockFebruary 5, 2025 | msn.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 14.0% in JanuaryCentury Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 3,090,000 shares, a growth of 14.0% from the December 31st total of 2,710,000 shares. Based on an average daily volume of 560,600 shares, the short-interest ratio is currently 5.5 days. Currently, 8.9% of the shares of the stock are short sold.February 1, 2025 | marketbeat.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Given Average Rating of "Buy" by BrokeragesCentury Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) has been given a consensus recommendation of "Buy" by the six ratings firms that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-yJanuary 22, 2025 | marketbeat.comGuggenheim Reaffirms "Buy" Rating for Century Therapeutics (NASDAQ:IPSC)Guggenheim reissued a "buy" rating on shares of Century Therapeutics in a research note on Wednesday.January 22, 2025 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Century Therapeutics in a report on Wednesday.January 22, 2025 | marketbeat.comCentury Therapeutics launches cell therapy trial for autoimmune diseasesJanuary 21, 2025 | msn.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 14.0% in DecemberCentury Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 3,090,000 shares, a growth of 14.0% from the December 15th total of 2,710,000 shares. Based on an average daily trading volume, of 560,600 shares, the short-interest ratio is presently 5.5 days. Approximately 8.9% of the shares of the stock are sold short.January 18, 2025 | marketbeat.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Down 5.6% in DecemberCentury Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 2,710,000 shares, a decline of 5.6% from the November 30th total of 2,870,000 shares. Based on an average daily trading volume, of 545,600 shares, the days-to-cover ratio is presently 5.0 days. Currently, 7.8% of the company's shares are sold short.January 1, 2025 | marketbeat.comCentury Therapeutics price target lowered to $4 from $12 at Piper SandlerDecember 30, 2024 | markets.businessinsider.comCentury Therapeutics (NASDAQ:IPSC) Given New $4.00 Price Target at Piper SandlerPiper Sandler cut their price target on shares of Century Therapeutics from $12.00 to $4.00 and set an "overweight" rating on the stock in a research report on Monday.December 30, 2024 | marketbeat.comPhiladelphia cell therapy developer loses Big Pharma partnership valued at over $3BDecember 17, 2024 | bizjournals.comFmr LLC Cuts Stake in Century Therapeutics, Inc. (NASDAQ:IPSC)Fmr LLC lowered its position in Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) by 14.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,521,511 shares of the company's stock after selling 428,768 shares during the quarter. Fmr LLC ownedDecember 14, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Trading Down 4.3% - Here's What HappenedCentury Therapeutics (NASDAQ:IPSC) Shares Down 4.3% - Here's What HappenedDecember 12, 2024 | marketbeat.comCentury Therapeutics to Present at Piper Sandler 36th Annual Healthcare ConferenceNovember 29, 2024 | msn.comLeerink Partners Reaffirms Their Buy Rating on Century Therapeutics (IPSC)November 28, 2024 | markets.businessinsider.comCentury Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | globenewswire.comWhat is HC Wainwright's Forecast for IPSC FY2024 Earnings?Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Equities researchers at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for Century Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. HC Wainwright analyst M. Kapoor now anticNovember 8, 2024 | marketbeat.comWhat is William Blair's Forecast for IPSC FY2024 Earnings?Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Research analysts at William Blair upped their FY2024 earnings per share (EPS) estimates for shares of Century Therapeutics in a report released on Tuesday, November 5th. William Blair analyst S. Corwin now expects that the company will posNovember 8, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Given New $11.00 Price Target at Chardan CapitalChardan Capital lowered their price target on Century Therapeutics from $17.00 to $11.00 and set a "buy" rating for the company in a research report on Thursday.November 7, 2024 | marketbeat.comCentury Therapeutics Reports Q3 Results & Strategic UpdatesNovember 6, 2024 | markets.businessinsider.comJoin Century Therapeutics at Guggenheim’s Healthcare Innovation Conference!November 6, 2024 | msn.comHC Wainwright Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00HC Wainwright reduced their target price on Century Therapeutics from $9.00 to $5.00 and set a "buy" rating for the company in a report on Wednesday.November 6, 2024 | marketbeat.comCentury Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual MeetingNovember 5, 2024 | markets.businessinsider.comCentury Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 5, 2024 | globenewswire.comCentury Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation ConferenceNovember 4, 2024 | markets.businessinsider.comCentury Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation ConferenceNovember 4, 2024 | globenewswire.comWe're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn RateOctober 28, 2024 | finance.yahoo.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Sees Significant Growth in Short InterestCentury Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 3,490,000 shares, a growth of 6.4% from the September 15th total of 3,280,000 shares. Based on an average daily trading volume, of 331,100 shares, the short-interest ratio is presently 10.5 days. Approximately 10.8% of the shares of the company are sold short.October 16, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Stock, Short Interest ReportOctober 13, 2024 | benzinga.comWatch out, CFOs: cybercrime is booming, says former White House advisorSeptember 30, 2024 | fortune.comCentury Therapeutics Announces Strategic Leadership AppointmentsSeptember 27, 2024 | msn.comCentury Therapeutics Names Morgan Conn Chief Financial OfficerSeptember 26, 2024 | marketwatch.comCentury Therapeutics Appoints Morgan Conn As CFOSeptember 26, 2024 | markets.businessinsider.comCentury Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific OfficerSeptember 26, 2024 | globenewswire.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Stake Cut by Federated Hermes Inc.Federated Hermes Inc. decreased its holdings in shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) by 55.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 276,163 shares of the company's stocSeptember 23, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Shares Up 5.5%Century Therapeutics (NASDAQ:IPSC) Shares Up 5.5%September 10, 2024 | marketbeat.comCentury Therapeutics, Inc. Expected to Post Q3 2024 Earnings of ($0.41) Per Share (NASDAQ:IPSC)Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Research analysts at HC Wainwright increased their Q3 2024 earnings per share estimates for shares of Century Therapeutics in a note issued to investors on Thursday, August 15th. HC Wainwright analyst M. Kapoor now expects that the companyAugust 19, 2024 | marketbeat.comHC Wainwright Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $9.00HC Wainwright lowered their target price on Century Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a report on Thursday.August 15, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Issues Quarterly Earnings ResultsCentury Therapeutics (NASDAQ:IPSC - Get Free Report) announced its earnings results on Thursday. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.12. The business had revenue of $0.77 million for the quarter, compared to the consensus estimate of $0.55 million. Century Therapeutics had a negative return on equity of 59.74% and a negative net margin of 9,742.41%.August 11, 2024 | marketbeat.comBuy Rating for Century Therapeutics Amidst Shift in Cell Therapy Market and Safety Concerns of CompetitorsAugust 10, 2024 | markets.businessinsider.comHold Rating on Century Therapeutics Amid Early-Stage Trials and Competitive LandscapeAugust 9, 2024 | markets.businessinsider.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Given Average Rating of "Moderate Buy" by AnalystsShares of Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommeAugust 8, 2024 | marketbeat.com Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Email Address IPSC Media Mentions By Week IPSC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPSC News Sentiment▼0.900.60▲Average Medical News Sentiment IPSC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPSC Articles This Week▼112▲IPSC Articles Average Week Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DSGN News CCCC News CRDF News ALMS News OGI News LFCR News CGEN News LRMR News AMRN News CTNM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IPSC) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IPSC Stock Alerts